Nordic Nanovector AS | Date: 2012-12-12
The present invention relates to chimieric or humanized antibodies derived from the mouse monoclonal antibody HH1. The applications of the present invention include therapeutic applications in which pharmaceutical compositions comprising the antibodies of the present invention or radioimmunoconjugates hereof are used for treating B-cell malignancies.
Nordic Nanovector As | Date: 2014-06-06
The present invention relates to radioimmunoconjugates that are capable of upregulating expression of one or more antigens. The upregulated antigens can be the antigens that are targeted by the radioimmunoconjugates or different antigens expressed on the same cells. The present invention also relates to methods of treating cancer and diseases and disorders of the immune system by utilizing this enhanced expression of antigens.
Nordic Nanovector As | Date: 2011-01-28
The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancerand in particular B-cell malignanciesare aspects of the present invention.
Nordic Nanovector AS | Date: 2013-12-09
The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer and in particular B cell malignancies are aspects of the present invention.
Nordic Nanovector AS | Date: 2014-03-12
The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer - and in particular B-cell malignancies - are aspects of the present invention.
News Article | February 20, 2017
OSLO (Reuters) - Norwegian biotech newcomer Nordic Nanovector , which seeks ways to treat blood-related cancers, says other companies are showing interest in buying the firm.
News Article | February 22, 2017
Nordic Nanovector ASA (OSE: NANO), a biopharmaceutical company focusing on the development and commercialisation of novel targeted therapeutics for haematological cancers, will announce its fourth quarter and full year 2016 results on Tuesday, 28th of February 2017. A presentation by Nordic Nanovector's senior management team will take place at 8:30 am CET at: The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investor Relations/Webcast. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Quarterly Reports/2016 from 7:00 am CET the same day. For further information, please contact: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other cancer therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision http://news.cision.com http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-fourth-quarter-and-full-year-2016-results-presentation-and-webc,c2195319
News Article | February 28, 2017
2016 var et svært godt år for Nordic Nanovector. Selskapet nådde viktige milepæler i utviklingen av sin fremste produktkandidat, Betalutin®. I tillegg hadde selskapet fremgang med prekliniske produktkandidater og la grunnlaget for innovasjon og utvikling av produktporteføljen innen målrettede behandlingsformer for hematologisk kreft. Den vellykkede kapitalinnhentingen på 499 millioner kroner i desember var en viktig milepæl som gjør selskapet i stand til å jobbe i tråd med sin langsiktige ambisjon. Den styrkede finansielle posisjonen gir et godt grunnlag for arbeidet med å maksimere verdien av Nordic Nanovectors unike biofarmasøytiske produktkandidater. Disse er Betalutin®, både separat og i kombinasjon med rituximab, samt den kreftsøkende anti-CD37 anti-radionuklide-konjugaten (ARC) i alle faser av follikulært lymfom (FL) og i andre hematologiske kreftindikasjoner. Selskapet jobber med å tilrettelegge for kommersialisering av Betalutin® og selektiv utvidelse av produktporteføljen for å utnytte intern og ekstern innovasjonskraft og ekspertise innen ARC og konjugater bestående av antistoffer og legemidler (ADC). Selskapets forventning til Betalutin® i fremskreden lymfekreft (3. linje) av typen FL ble bekreftet gjennom fjerde kvartal i 2016. På bakgrunn av anbefalinger fra studiens uavhengige sikkerhetskomite blir et nytt, høyere doseringsregime testet i studien Lymrit 37-01. Pasientrekruttering til Arm 4 er i rute for seleksjonen av optimal doseringsstørrelse for den endelige fase 2-studien PARADIGME, som er planlagt å starte i andre halvår 2017. De oppdaterte resultatene fra studiene som ble presentert på konferansen American Society of Hematology (ASH) i desember 2016, fortsetter å bygge opp under den lovende kliniske profilen for Betalutin® i fremskreden lymfekreft (3.linje) av typen FL. Den synergistiske effekten av Betalutin® i kombinasjon med rituximab i en preklinisk test (in vivo-modell) av lymfekreftformen non-Hodgkin's lymfom (NHL) ble også presentert på ASH. Dataene støtter selskapets beslutning om å videreføre denne kombinasjonen til klinisk utvikling rettet mot fremskreden FL i 2. linje. I tillegg var den prekliniske utviklingen med kreftsøkende anti-CD37 ARC vellykket, og selskapet planlegger å starte de første kliniske studiene i løpet av 2017. Potensialet for tilgang til det totale markedet for FL representerer en betydelig større markedsmulighet for Nordic Nanovectors kandidater enn for kun fremskreden lymfekreft i 3. linje FL. Som en del av Nordic Nanovectors strategi for en bredere produktportefølje, har selskapet inngått samarbeidsavtaler med LegoChem og Heidelberg Pharma for å utforske potensialet til ADC med toksiner i stedet for radionuklider for behandling av leukemi. «Selskapet har hatt meget god fremgang gjennom 2016 og har nådd viktige milepæler. Det gir et solid momentum inn i 2017. Vi forventer ferdigstillelse av den pågående kliniske studien av Betalutin®, Lymrit 37-01, og beslutning om dosestørrelse for den avgjørende fase 2-studien senere i år. I tillegg har den nylige kapitaltilførselen gjort selskapet i stand til å forfølge flere muligheter med antatt verdi innenfor NHL og potensielt også i andre blodkrefttyper. Vi ser frem imot et spennende år», sier Luigi Costa, administrerende direktør i Nordic Nanovector. - Lymrit 37-01-studien fortsetter med høyere dosering for Betalutin® i Arm 4 o Rekruttering og behandling i Arm 4 er i rute for evaluering og seleksjon for doseringsregimet av den uavhengige sikkerhetskomiteen for den avgjørende fase 2-studien PARADIGME - Resultater presentert på ASH 2016 fortsetter å understøtte Betalutin®'s lovende kliniske profil o Betydelig anti-svulst aktivitet observert i monoterapi: ORR 62 %, CR 38 % i Arm 1-pasienter som mottok 15 MBq/kg; konsistent for 16 pasienter behandlet i Arm 1/fase 2 (ORR 69 %, CR 38 %) o Varig respons observert: medianvarigheten for respons er 20,7 måneder for pasienter i Arm 1 o Forutsigbar og håndterbar sikkerhetsprofil - Videre fremgang innen utviklingsporteføljen o Har inngått FoU-samarbeid med LegoChem Biosciences og Heidelberg Pharma for å utforske potensialet til ADC med toksiner i stedet for radionuklider for behandling av leukemi - Nye medlemmer i toppledelsen og styret o Dr Lisa Rojkjaer, MD, ansatt som Chief Medical Officer(CMO) o Dr Joanna Horobin, MD, valgt som styremedlem - Tilførsel av frisk kapital muliggjør utvidet utviklingsstrategi for målrettede behandlingsformer o Vellykket emisjon på 499 millioner kroner brutto i desember 2016 - Beslutninger om å starte kliniske programmer mot 1. og 2. linje lymfekreft av typen FL i 2017 støttet av prekliniske data o Resultatene presentert på ASH viser synergier for anti-svulst- effekten av Betalutin® i kombinasjon med rituximab - De første sykehusene USA er nå åpne for fase 1-studier for pasienter med tilbakefall av DLBCL Selskapet ønsker å utnytte fremgangen og sin styrkede finansielle posisjon til å drive en forlenget og utvidet strategi for å nå sine langsiktige ambisjoner: Maksimere verdien av selskapets målrettede biofarmasøytiske kandidater gjennom alle faser av FL og andre store hematologiske kreftindikasjoner for å forberede kommersialiseringen av Betalutin® og selektivt utvide produktporteføljen. Markedsforholdene for Betalutin® er fortsatt lovende. Sterke resultater og god fremdrift i den kliniske studien for Lymrit 37-01 lover godt for beslutningen om doseringsregime for Betalutin® i fase 2. Ledelsen vil fortsette å rette innsatsen mot effektiv utøvelse av planer for å nå de forventede kliniske milepælene. Selskapets kontantbeholdning er forventet å være tilstrekkelig til å nå den regulatoriske godkjenningssøknaden for Betalutin® som er planlagt i første halvdel av 2019, og til å oppnå verdigenererende kliniske milepæler i de øvrige programmene. Selskapets ledelse gir en presentasjon av resultatene i dag klokken 08:30. Sted: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Møterom: NYLAND Presentasjonen kan følges direkte på www.nordicnanovector.com under Investor Relations / Webcast. Resultatrapporten og presentasjonen er tilgjengelig på www.nordicnanovector.com under seksjonen Investor Relations / Quarterly reports/ 2016 fra klokken 07:00 i dag. Nordic Nanovector arbeider med utvikling og kommersialisering av innovativ behandling til pasienter for å møte store udekkede behandlingsbehov og videreutvikle kreftbehandling. Selskapet har ambisjoner om å bli en ledende aktør innen utviklingen av målrettet behandling for hematologisk kreft. Nordic Nanovectors ledende legemiddelkandidat under klinisk utvikling er Betalutin®, et målrettet CD37 antistoff-radionuklid-konjugat (ARC) utviklet for å forbedre og supplere dagens behandlingsalternativ for pasienter med lymfekreftformen non-Hodgkin's Lymfom (NHL). NHL er en indikasjon med et stort udekket behandlingsbehov og muligheter for såkalt «orphan drugs designation» , en incentivordning for få frem nye legemidler til sjeldne sykdommer. NHL representerer er et voksende marked med et antatt markedspotensial på omkring 20 milliarder amerikanske dollar innen 2024. Selskapet har som mål å utvikle Betalutin®, både alene og i kombinasjon med andre behandlingsformer, for behandling av varianter av NHL, og regner med å sende den første regulatoriske søknaden for fremskreden follikulært lymfom i løpet av første halvår av 2019. Nordic Nanovector planlegger å beholde markedsføringsrettighetene og delta aktivt i kommersialiseringen av Betalutin® i viktige markeder. Selskapet arbeider også med utvikling av en produktportefølje med ARC og andre immunterapier for flere kreftindikasjoner. Ytterligere informasjon om selskapet er tilgjengelig på www.nordicnanovector.com This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act. This information was brought to you by Cision http://news.cision.com http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---resultater-for-fjerde-kvartal-og-helar-2016,c2200992 The following files are available for download:
News Article | February 28, 2017
Nordic Nanovector ASA (OSE: NANO) announces its results for the fourth quarter and full year 2016. A presentation of the results by the company's senior management team will take place today at 8:30 a.m. CET in Oslo - details below. 2016 was a very successful year for Nordic Nanovector. We achieved important milestones with regard to the clinical development of Betalutin®, progressed with our preclinical candidates and build the foundation of R&D innovation and expertise for the development of a pipeline of novel targeted therapies for major haematological cancers. The successful completion of a NOK 499 million private placement in December was a key event that will enable the company to work towards its broader long-term ambition. With its strengthened financial position, Nordic Nanovector aims at maximizing the value of its novel targeted biopharmaceutical candidates (Betalutin®, alone and in combination with rituximab, and the chimeric anti-CD37 ARC) across all stages of follicular lymphoma (FL) and other major haematological cancer indications. The company intends to prepare for the commercialisation of Betalutin®, and to selectively extend its pipeline leveraging internal and external innovation and expertise in ARCs and ADCs. The company's confidence in Betalutin® in 3rd line FL was confirmed during the fourth quarter 2016. On the basis of recommendations from the trial's Safety Review Committee, a new, higher dosing regimen is being tested in the Lymrit 37-01 trial. Patient recruitment into Arm 4 of the study is on track to enable the selection of an optimal dosing regimen for the pivotal Phase 2 PARADIGME trial, which is planned to start in the second half of 2017. Updated results from the trial presented at ASH 2016 in December continue to support the promising clinical profile of Betalutin® in 3rd line FL. The synergistic anti-tumour effect of Betalutin® in combination with rituximab in a preclinical in vivo model of NHL, was also presented at ASH. These data support the company's decision to advance this combination into clinical development targeting 2nd line FL. Furthermore, preclinical development with the chimeric anti-CD37 ARC was completed successfully, and the company plans to start first clinical studies during 2017. The potential to access the combined FL market presents a significantly larger market opportunity for Nordic Nanovector's candidates than 3rd line FL alone. Finally, as part of its strategy to broaden and diversify its pipeline, the company entered collaboration agreements with LegoChem and Heidelberg Pharma to explore potential of ADCs with non-radionuclide payloads for the treatment of leukaemias. Luigi Costa, CEO of Nordic Nanovector, comments: "The company has made excellent progress during 2016 reaching significant milestones across the business and generating important momentum going into 2017. In particular, we anticipate the completion of the Lymrit 37-01 study with Betalutin® and the selection of a dosing regimen to take into the pivotal Phase 2 trial later in the year. Also, the recent financing is enabling the company to pursue multiple opportunities to capture more value across the NHL space and potentially beyond into other haematological cancers. We are looking forward to an exciting year ahead." • Lymrit 37-01 trial advancing with a higher dosing regimen for Betalutin® in Arm 4 o Recruitment and treatment into Arm 4 on-track for a timely SRC evaluation and selection of dosing regimen for pivotal Phase 2 PARADIGME trial • Results presented at ASH 2016 continue to highlight Betalutin®'s promising clinical profile o Significant anti-tumour activity observed in monotherapy: ORR of 62%, CR 38% in Arm 1 patients receiving 15MBq/kg; consistent for 16 patients treated in Arm 1/Phase 2 (ORR 69%, CR 38%) o Durable responses observed: median duration of response of 20.7 months for patients in Arm 1 o Well tolerated with predictable and manageable safety profile • Further progress on R&D pipeline o Entered into R&D collaborations with LegoChem Biosciences and Heidelberg Pharma to explore potential of ADCs with non-radionuclide payloads for the treatment of leukaemias • New members join Executive Management Team and Board of Directors o Dr Lisa Rojkjaer, MD, joined as Chief Medical Officer o Dr Joanna Horobin, MD, elected as Non-executive Director • New funds raised enable expanded and extended development strategy for novel targeted therapeutics o Successful private placement raised NOK 499 million in gross proceeds (December 2016) • Decision to initiate clinical programmes targeting 2nd and 1st line FL in 2017 supported by preclinical data o Results presented at ASH 2016 show synergistic anti-tumour effect of Betalutin® in combination with rituximab • First sites in US are now open for the Phase 1 study in relapsed DLBCL Financial Highlights Fourth Quarter and Full Year 2016 (Figures in brackets = same period 2015 unless otherwise stated) • Revenues in the fourth quarter 2016 amounted to NOK 0.079 million (NOK 0.143 million). Revenues for the full year 2016 were NOK 0.314 million (NOK 0.437 million). • Total operating expenses for the fourth quarter were NOK 65.4 million (NOK 33.4 million). Total operating expenses for the full year 2016 were NOK 216.7 million (NOK 183.5 million). • Comprehensive loss for the fourth quarter amounted to NOK 59.3 million (loss of NOK 31.0 million). Comprehensive loss for the full year 2016 was NOK 235.8 million (NOK 173.1 million). • Cash and cash equivalents amounted to NOK 1,018.2 million at the end of December 2016 (NOK 560.1 million at the end of September 2016 and NOK 743.4 million at the end of December 2015). Looking forward, the company intends to leverage this progress and its strengthened financial position to drive an expanded and extended strategy towards achieving its broader long-term ambitions: maximize the value of its novel targeted biopharmaceutical candidates across all stages of FL and other major haematological cancer indications, to prepare for the commercialisation of Betalutin® and to selectively extend its pipeline. The competitive profile for Betalutin® remains promising. Strong results and good progress in the Lymrit 37-01 clinical study give the company confidence that it is on track to select a dosing regimen for Betalutin® in Phase 2. Management will continue to focus its efforts on the efficient execution of its plans and to meet anticipated clinical milestones. Current cash resources are now expected to be sufficient to take the company beyond a planned first regulatory submission for Betalutin® in FL in the first half of 2019 and to meet value-generating clinical milestones in its other programmes. A presentation by Nordic Nanovector's senior management team will take place today at 8:30 a.m. CET at: The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investor Relations/Webcast. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Quarterly Reports/2016 from 7:00 am CET today. For further information, please contact: Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other cancer therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com This announcement may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of Nordic Nanovector's strategy and its ability to further grow, risks associated with the development and/or approval of Nordic Nanovector's products candidates, ongoing clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act. This information was brought to you by Cision http://news.cision.com http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---results-for-fourth-quarter-and-full-year-2016,c2200978 The following files are available for download:
News Article | February 23, 2017
HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor, Johnson & Johnson Innovation – JJDC, Inc., with investments by HealthCap, TPG Biotech, Genesys Capital and FACIT (Fight Against Cancer Innovation Trust). Targeted alpha-particle emitting radiotherapeutics combine the precision of molecular targeting agents, such as antibodies with the potency of alpha-particle emitting radioisotopes to specifically attack and eradicate cancer cells. The syndicate is strengthened by HealthCap’s specialized expertise in pioneering a new wave of successful radiotherapeutic companies, such as Algeta and Nordic Nanovector. Fusion Pharmaceuticals is a spinout from the Centre for Probe Development and Commercialization (CPDC), an organization that Dr. John Valliant, Ph.D., founded in 2008 and is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. The CPDC, which was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE) and the Ontario Institute for Cancer Research (OICR), has rapidly become a world leader in the development, translation and manufacturing of radiopharmaceuticals. In addition to Dr. Valliant, founder and chief executive officer, the company’s board of directors consists of Asish Xavier, Ph.D. (Johnson & Johnson Innovation – JJDC, Inc.), Robert Sutherland, Ph.D., Centre for Probe Development and Commercialization (CPDC), Eran Nadav, Ph.D. (TPG Biotech), Johan Christenson, M.D. (HealthCap) and Damian Lamb (Genesys), who will assume the role of chairman of the board. “Targeted delivery of medical isotopes that emit alpha particles can be used to kill tumor cells with remarkable precision and unprecedented potency, and it has the added potential of having complementary effects with treatments which activate the immune system,” said Dr. John Valliant, CEO. “Fusion is focused on combining our expertise in radiopharmaceutical development and production with the appropriate targeting molecules to create a new generation of therapeutics that can address the need for better cancer treatments. Fusion is proud to join a wave of new Canadian biotech companies that are being launched with innovative technologies emerging from research institutions like McMaster University.” Fusion Pharmaceuticals will use the financing proceeds to advance its lead program, FPX-01, into human clinical trials. FPX-01 is an antibody-targeted radiotherapy, which seeks out a specific biomarker of resistance that is present on nearly all types of treatment refractory cancers. The technology is designed to selectively deliver actinium-225 to tumor cells so that in conjunction with internalization, the alpha particles emitted will eradicate diseased tissue. In parallel, Fusion Pharmaceuticals gained access to a centyrin-based targeting molecule in preclinical development that has the potential to deliver isotopes to several cancer types and access to the centyrin protein targeting platform in two licensing agreements with Janssen Biotech, Inc. in transactions facilitated by Johnson & Johnson Innovation. Centyrins are protein targeting agents, proprietary to Janssen Biotech, characterized by high selectivity and specificity, combined with tunable pharmaceutical properties and efficient manufacturing. Fusion Pharmaceuticals is building its pipeline through access to the centyrin platform in combination with proprietary labeling technologies, which can be applied to a wide range of targeting molecules. Fusion Pharmaceuticals – A Product of a National Centre of Excellence with Comprehensive Sector Expertise Fusion Pharmaceuticals is a spin out from the Centre for Probe Development and Commercialization (CPDC), which is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University. The CPDC was created to take promising new technologies developed at Universities and use the arising knowledge advantages to realize economic and health benefits for Canadians. The CPDC, which employs over 80 people and has locations and major partnerships in Hamilton, Toronto, Ottawa and Boston, is supported by a range of stakeholders including the Networks of Centres of Excellence, the Ontario Institute for Cancer Research, McMaster University and several industry partners. See www.imagingprobes.ca for additional details. Fusion Pharmaceuticals was founded by Dr. John Valliant, who was also the founder and CEO of CPDC. Under Dr. Valliant’s direction, the CPDC supplied radiopharmaceuticals for over 40 clinical trials, facilitated the creation of three new companies, including building a rapidly expanding manufacturing business. Dr. Valliant, a Canada Research Chair in Medical Isotopes and Molecular Imaging Probes, is a Professor of Chemistry and Chemical Biology at McMaster University. He has won numerous awards including being selected as one of Canada’s top 40 under 40 in 2010. Fusion’s discovery and development programs are led by the chief scientific officer, Dr. Eric Burak, Ph.D. Eric previously held positions at CPDC, Theracos, Rib-X Pharmaceuticals and Guilford Pharmaceuticals. Eric oversees a world-class team of chemists and biologists who have extensive experience and unique skills in the alpha therapy field. Certain medical isotopes emit alpha particles, which are highly energetic ions that deposit their energy over very short distances traveling approximately the width of a single cell. When alpha emitting medical isotopes are delivered to cancer cells, they can kill tumor cells through multiple mechanisms including double stranded DNA breaks, which makes repair and hence resistance unlikely. Targeted alpha therapeutics use significantly smaller amounts of material than typical antibody-drug conjugates making it possible to exploit a wider array of drug targets and they do not require complex linkers to release the warhead. One of the additional benefits of Fusion’s alpha therapeutic approach will be creation of a companion diagnostic with each candidate. Fusion Pharmaceuticals is a new pharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01, Fusion is building a pipeline of products through a protein discovery platform, that allows for the rapid screening of new targeting molecules to promote biomarker localization of alpha emitting medical isotopes. Fusion’s technology development team also has proprietary methods for introducing alpha emitters into targeting molecules. (http://www.fusionpharma.com)